Clinical Trial Update: Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

This is a Phase 2 trial update on the combination of SAR3419 and rituximab in relapsed/refractory diffuse large B-cell lymphoma. The update notes completion of …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• SAR3419

Snippet

Sponsor: Sanofi | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: COMPLETED